Evidence Summaries 5-HT3 receptor antagonists alone or combined with steroids are effective for chemotherapy induced nausea and vomiting compared to placebo or conventional anti-emetics.
A systematic review 1 comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting included 30 RCTs. 5-HT3 antagonists reduced the risk of acute vomiting compared to conventional anti-emetics both with cisplatin treatments (OR 0.60, 95% CI 0.51 to 0.70; 15 studies) and with moderately emetogenic treatments (OR 0.47, 95% CI 0.39 to 0.58; 11 studies). The risk of acute vomiting seemed to be further reduced when 5-HT3 antagonists were combined with dexamethasone.
Another systematic review and network meta-analysis 2 on 5-HT3 receptor antagonists (dolasetron, granisetron, ondansetron, palonosetron, tropisetron) for patients undergoing chemotherapy included 299 studies with a total of 58,412 subjects.
In the network meta-analysis, all 5-HT3 receptor antagonists were effective for reducing risk of nausea (44 studies, n=11,664, 12 treatments), vomiting (63 studies, n=15,460, 12 treatments), and chemotherapy-induced nausea or vomiting (27 studies, n=10,924, 9 treatments) compared to placebo. All treatments decreased the risk of severe vomiting (10 studies, n=917), but only ondansetron and ramosetron were significantly superior to placebo. According to the rank-heat plot, palonosetron + steroid was most likely the safest and most effective treatment. Across the effectiveness outcomes, the following treatments ranked as most superior on 3 effectiveness outcomes during the first 24 h after chemotherapy for adults: ondansetron + steroid, palonosetron + steroid, granisetron + steroid, and ramosetron + steroid.
. Jantunen IT, Kataja VV, Muhonen TT. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 1997 Jan;33(1):66-74. [PMID:9071902]
. Tricco AC, Blondal E, Veroniki AA et al. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. BMC Med 2016;14(1):216. [PMID:28007031]
Copyright © 2023 Duodecim Medical Publications Limited.
"5-HT3 Receptor Antagonists in Chemotherapy-induced Nausea and Vomiting." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/451268/all/5_HT3_receptor_antagonists_in_chemotherapy_induced_nausea_and_vomiting.
5-HT3 receptor antagonists in chemotherapy-induced nausea and vomiting. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/451268/all/5_HT3_receptor_antagonists_in_chemotherapy_induced_nausea_and_vomiting. Accessed December 9, 2023.
5-HT3 receptor antagonists in chemotherapy-induced nausea and vomiting. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/451268/all/5_HT3_receptor_antagonists_in_chemotherapy_induced_nausea_and_vomiting
5-HT3 Receptor Antagonists in Chemotherapy-induced Nausea and Vomiting [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 December 09]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/451268/all/5_HT3_receptor_antagonists_in_chemotherapy_induced_nausea_and_vomiting.
TY - ELEC
T1 - 5-HT3 receptor antagonists in chemotherapy-induced nausea and vomiting
ID - 451268
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/451268/all/5_HT3_receptor_antagonists_in_chemotherapy_induced_nausea_and_vomiting
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine